<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671239</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-035</org_study_id>
    <secondary_id>UM1AI068633</secondary_id>
    <secondary_id>UM1AI068615</secondary_id>
    <secondary_id>UM1AI106707</secondary_id>
    <secondary_id>38459</secondary_id>
    <nct_id>NCT03671239</nct_id>
  </id_info>
  <brief_title>Rectal Microbicide Acceptability, Tolerability and Adherence</brief_title>
  <official_title>Acceptability, Tolerability, and Adherence of Three Rectal Microbicide Placebo Formulations Among HIV Seronegative Cisgender Men, Transgender Men and Transgender Women Who Engage in Receptive Anal Intercourse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microbicide Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Microbicide Trials Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that&#xD;
      will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences&#xD;
      of rectal microbicide placebo product application.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that&#xD;
      will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences&#xD;
      of rectal microbicide placebo product application. At the start of each 4-week product use&#xD;
      period, participants will receive either rectal inserts, rectal douches, or rectal&#xD;
      suppositories and be instructed to use their assigned study product prior to each receptive&#xD;
      anal intercourse (RAI) encounter during that period. Participants who do not have RAI in a&#xD;
      given week will be asked to use the product without sex. There will be a 1-week washout&#xD;
      period between each of the three product use periods. Participant follow-up will take&#xD;
      approximately 3.5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Actual">July 27, 2020</completion_date>
  <primary_completion_date type="Actual">July 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Likelihood of Future Product Use Scale</measure>
    <time_frame>14 weeks (three 4-week product use periods with 1-week washout periods between them)</time_frame>
    <description>On a scale of 1 (low likelihood) to 10 (high likelihood), participant self-report of likelihood of product use if product is shown to be effective</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to Placebo Products</measure>
    <time_frame>14 weeks (three 4-week product use periods with 1-week washout periods between them)</time_frame>
    <description>Percentage of occasions when each study product was used as instructed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Grade 2+ Adverse Events</measure>
    <time_frame>14 weeks (three 4-week product use periods with 1-week washout periods between them)</time_frame>
    <description>Number of all Grade 2 or higher adverse events (AE) as defined by the DAIDS AE Grading Table</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>Product Sequence A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Sequence F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo rectal insert</intervention_name>
    <description>Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.</description>
    <arm_group_label>Product Sequence A</arm_group_label>
    <arm_group_label>Product Sequence B</arm_group_label>
    <arm_group_label>Product Sequence C</arm_group_label>
    <arm_group_label>Product Sequence D</arm_group_label>
    <arm_group_label>Product Sequence E</arm_group_label>
    <arm_group_label>Product Sequence F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo rectal suppository</intervention_name>
    <description>Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.</description>
    <arm_group_label>Product Sequence A</arm_group_label>
    <arm_group_label>Product Sequence B</arm_group_label>
    <arm_group_label>Product Sequence C</arm_group_label>
    <arm_group_label>Product Sequence D</arm_group_label>
    <arm_group_label>Product Sequence E</arm_group_label>
    <arm_group_label>Product Sequence F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo rectal douche</intervention_name>
    <description>Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.</description>
    <arm_group_label>Product Sequence A</arm_group_label>
    <arm_group_label>Product Sequence B</arm_group_label>
    <arm_group_label>Product Sequence C</arm_group_label>
    <arm_group_label>Product Sequence D</arm_group_label>
    <arm_group_label>Product Sequence E</arm_group_label>
    <arm_group_label>Product Sequence F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men (cis or transgender) and TGW who are 18-35 years old at Screening, verified per&#xD;
             site SOP.&#xD;
&#xD;
          2. Able and willing to provide written informed consent.&#xD;
&#xD;
          3. HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix&#xD;
             II and willing to receive HIV test results.&#xD;
&#xD;
          4. Able and willing to provide adequate locator information, as defined in site SOP.&#xD;
&#xD;
          5. Available to return for all study visits and willing to comply with study&#xD;
             participation requirements.&#xD;
&#xD;
          6. In general good health at Screening and Enrollment, as determined by the site&#xD;
             Investigator of Record (IoR) or designee.&#xD;
&#xD;
          7. At Screening, history of consensual RAI at least three times in the past three months&#xD;
             and expecting to maintain at least this frequency of RAI during study participation&#xD;
             per participant report.&#xD;
&#xD;
          8. Willing to not take part in other research studies involving drugs, medical devices,&#xD;
             genital or rectal products, or vaccines for the duration of study participation&#xD;
             (including the time between Screening and Enrollment).&#xD;
&#xD;
          9. For individuals who can get pregnant (i.e., TGM with a female reproductive system): a&#xD;
             negative pregnancy test at Screening and Enrollment.&#xD;
&#xD;
         10. For individuals who can get pregnant: Per participant report at Enrollment, using an&#xD;
             effective method of contraception for at least 30 days (inclusive) prior to Enrollment&#xD;
             and intending to use an effective method for the duration of study participation;&#xD;
             effective methods include:&#xD;
&#xD;
               1. Hormonal methods;&#xD;
&#xD;
               2. Intrauterine device (IUD) inserted at least 30 days prior to Enrollment (but not&#xD;
                  past the maximum length of recommended usage according to package instructions);&#xD;
&#xD;
               3. Sterilization (of participant or, if in a monogamous relationship, of partner, as&#xD;
                  defined in site SOPs);&#xD;
&#xD;
               4. Abstinence from RVI for 90 days prior to Enrollment, and intention to abstain&#xD;
                  from RVI for the duration of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. At Screening:&#xD;
&#xD;
               1. History of inflammatory bowel disease;&#xD;
&#xD;
               2. Current anorectal condition that would impede product placement or assessment of&#xD;
                  tolerability by participant report or exam.&#xD;
&#xD;
          2. Anticipated use and/or unwillingness to abstain from using non-study&#xD;
             rectally-administered medications and products during study participation, including&#xD;
             personal lubricants containing nonoxynol-9 (N-9).&#xD;
&#xD;
             Note: The use of non-study personal lubricants and usual pre-RAI douches that do not&#xD;
             contain N-9 is permitted during study participation.&#xD;
&#xD;
          3. Known adverse reaction to any of the components of the study products.&#xD;
&#xD;
          4. Participation in research studies involving drugs, medical devices, genital products,&#xD;
             or vaccines within 30 days of the Enrollment Visit.&#xD;
&#xD;
          5. Participation in research studies involving rectal products (ever).&#xD;
&#xD;
          6. Per participant report, use of post-exposure prophylaxis (PEP) for potential HIV&#xD;
             exposure within the 3 months prior to Enrollment.&#xD;
&#xD;
          7. In the 3 months prior to Enrollment, participant engagement in condomless RAI or RVI&#xD;
             while not on PrEP with a partner who is HIVpositive and either not on ART or of&#xD;
             unknown ART use status (by self report).&#xD;
&#xD;
          8. In the month prior to Enrollment, participant engagement in condomless RAI or RVI&#xD;
             while not on PrEP with a partner who is of unknown HIV status and unknown PrEP/ART use&#xD;
             status (by self-report).&#xD;
&#xD;
          9. Non-therapeutic injection drug use in the 12 months prior to Enrollment.&#xD;
&#xD;
         10. At either Screening or Enrollment, participant-reported symptoms and/or clinical or&#xD;
             laboratory diagnosis of active anorectal or reproductive tract infection (RTI)&#xD;
             requiring treatment per current WHO guidelines (http://www.who.int/hiv/&#xD;
             pub/sti/pub6/en/), or symptomatic urinary tract infection (UTI). Infections requiring&#xD;
             treatment include: Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), syphilis,&#xD;
             active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic&#xD;
             genital warts, chancroid, pelvic inflammatory disease (PID), symptomatic bacterial&#xD;
             vaginosis (BV), symptomatic vaginal candidiasis, and trichomoniasis.&#xD;
&#xD;
             Note: Otherwise eligible participants with a symptomatic UTI or an STI/RTI requiring&#xD;
             treatment per current WHO guidelines may be retested during the screening process and&#xD;
             if treatment is completed and symptoms have resolved within the screening window the&#xD;
             participant may be enrolled.&#xD;
&#xD;
             Note: HSV-1 or HSV-2 seropositive diagnosis with no active lesions is permitted since&#xD;
             treatment is not required.&#xD;
&#xD;
         11. For individuals who can get pregnant: Pregnant or breastfeeding at either Screening or&#xD;
             Enrollment or planning to become pregnant during study participation.&#xD;
&#xD;
         12. For individuals who can get pregnant: Last pregnancy outcome 90 days or less prior to&#xD;
             Screening.&#xD;
&#xD;
         13. Has any other condition that, in the opinion of the IoR/designee, would preclude&#xD;
             informed consent, make study participation unsafe, complicate interpretation of study&#xD;
             outcome data, or otherwise interfere with achieving study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cisgender men, transgender men (TGM) and transgender women (TGW)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos√© A Bauermeister, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge HIV Clinical Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Clinical Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blantyre Clinical Research Site</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Miguel Clinical Research Site</name>
      <address>
        <city>San Miguel</city>
        <zip>15088</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute Clinical Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2038</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University HIV Prevention Clinical Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50202</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acceptability</keyword>
  <keyword>Rectal microbicide</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03671239/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03671239/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03671239/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

